Status:
WITHDRAWN
Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Lead Sponsor:
Washington University School of Medicine
Conditions:
Migraine in Children
Pain, Neuropathic
Eligibility:
All Genders
8-17 years
Phase:
PHASE2
Brief Summary
Single-center, open-label, pre-post treatment pilot study to evaluate the safety and effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the pediatric population. 5...
Eligibility Criteria
Inclusion
- Children ages 8 to 17 years old Meet the criteria for chronic migraines Have remained stable on their current headache medication for a minimum of 4 weeks.
- Able to provide informed consent from parent or legal guardian Able to provide assent if subject is a minor of appropriate age
Exclusion
- Allergy to local anesthetic Developmental delay (e.g. non-verbal) Inability to use numeric pain scale Inability to perform or tolerate transnasal procedure Substance abuse disorders Known pregnancy
Key Trial Info
Start Date :
January 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 5 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04466826
Start Date
January 2 2021
End Date
February 5 2021
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Louis Children's Hospital
St Louis, Missouri, United States, 63110